Oculus product has applications in multiple multi-billion dollar markets (NASDAQ:OCLS)
BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has issued a special report regarding Oculus Innovative Sciences, Inc and their biotechnology platform.
The “magic” of the product captured the attention of the investment community and speculators moved in. Shares traded as high as $11 in 2007 and in the $4 range as recently as last June.
Scientific studies showed time and again that their product has the ability to eradicate bacteria, spores and viruses but it’s the safety of the product that makes it fascinating. One can put it anywhere on one’s body and it will go to work without causing harm to living tissue or cells.
The company is in serious discussion with several partners to use their distribution platforms in order to get the product onto shelves all over the U.S., and announcements should follow in the near term.
The OTC version of the HydroGel product will be available to consumers beginning October 2009.
Until now, most of the company’s revenue has come from Mexico, where they move an average of over 35,000 units a month (approximately $5 to $6 million in revenue per year from just sales south of the border).
Using the market and usage indication data from that market, the company is preparing plans for expansion into Europe and China as well. That makes an investment in this company quite an interesting proposal.
Especially as investors consider the potential revenues which may come from the new additional sales in the U.S., and beyond. And that’s a point not missed by Oculus CEO, Hoji Alimi.
“Look at the population of China, for example. That’s a population ten times the size of Mexico. We have an approval. We have a partnership with the largest drug company in China.”
Investors are invited to read the full report at BioMedReports.Com
Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:
Disclosure: BiomedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
For more biomedical sector and investment news, go to www.BioMedReports.com
Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects” “anticipates” “plans” “believes” “scheduled” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
- Contact Information
- Mike Havrilla
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.